Skip to content

G&A at other companies

Vera Therapeutics logo
Vera TherapeuticsVERA
$39.12M+146%
Alumis Inc. logo
Alumis Inc.ALMS
$18.61M-16.5%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$21.95M+31.4%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$20.84M+10.8%

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's G&A?
Aurinia Pharmaceuticals (AUPH) reported G&A of $22.03M in Q1 2026.
How has Aurinia Pharmaceuticals's G&A changed year-over-year?
Aurinia Pharmaceuticals's G&A increased by 8.3% year-over-year, from $20.34M to $22.03M.
What is the long-term trend for Aurinia Pharmaceuticals's G&A?
Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's G&A has grown at a -12.5% compound annual growth rate (CAGR), from $173.54M to $101.79M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.